Development of Extragenital Lichen Sclerosus in Malignant Melanoma Patients Treated With Ipilimumab in Combination With Nivolumab

The immune checkpoint inhibitors opened a new era for the treatment of melanoma. Nowadays, combined immune checkpoint inhibitors are administered to provide additive or synergistic effects on anti-melanoma immunity. The use of these drugs comes with serious adverse events related to excessive immune...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in oncology 2020-10, Vol.10, p.573527
Main Authors: Seyed Jafari, S Morteza, Feldmeyer, Laurence, Hunger, Robert E
Format: Article
Language:English
Subjects:
checkpoint inhibitors
extragenital lichen sclerosus et atrophicus
ipilimumab
malignant melanoma
metastatic
nivolumab
Oncology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The immune checkpoint inhibitors opened a new era for the treatment of melanoma. Nowadays, combined immune checkpoint inhibitors are administered to provide additive or synergistic effects on anti-melanoma immunity. The use of these drugs comes with serious adverse events related to excessive immune activation. Here, we present development of extragenital lichen sclerosus in a patient with metastatic malignant melanoma, during the combined therapy with checkpoint inhibitors.
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2020.573527